OCUL - Ocular Therapeutix, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.3700
+0.1900 (+4.55%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.1800
Open4.2200
Bid4.3700 x 2900
Ask4.8000 x 1100
Day's Range4.1700 - 4.5000
52 Week Range2.3500 - 6.0500
Volume2221392
Avg. Volume493,760
Market Cap210M
Beta (3Y Monthly)2.21
PE Ratio (TTM)N/A
EPS (TTM)-1.7950
Earnings DateMar 5, 2020 - Mar 9, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.20
  • Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?
    Simply Wall St.

    Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Thomson Reuters StreetEvents

    Edited Transcript of OCUL earnings conference call or presentation 12-Nov-19 1:00pm GMT

    Q3 2019 Ocular Therapeutix Inc Earnings Call

  • Business Wire

    Ocular Therapeutix™ to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will present and host investor meetings at the Piper Jaffray 31st Annual Healthcare Conference being held at the Lotte ...

  • Business Wire

    Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference

    Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Donald Notman, Chief Financial Officer of Ocular Therapeutix, will give a company presentation on Thursday, November 21st at 8:40 a.m.

  • Ocular Therapeutix (OCUL) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Ocular Therapeutix (OCUL) Reports Q3 Loss, Misses Revenue Estimates

    Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 2.17% and -23.59%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Ocular Therapeutix™ Reports Third Quarter 2019 Financial Results and Business Update

    Over 7,000 Patients Treated Since Launch at more than 350 Surgical Sites

  • Business Wire

    Ocular Therapeutix Announces Strategic Update and Operational Restructuring

    Ocular Therapeutix, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced an operational restructuring plan. The Company estimates that it will record costs associated with the restructuring of approximately $0.7 million in the fourth quarter. The restructuring represents a strategic realignment and commitment by the Company to allocate capital and resources to maximize the commercial opportunity of DEXTENZA® and focus resources on progressing key pipeline assets, including completion of its DEXTENZA Phase 3 trial in allergic conjunctivitis and completion of Phase 1 trials of OTX-TIC for the treatment of glaucoma and ocular hypertension and OTX-TKI for the treatment of wet age-related macular degeneration.

  • Business Wire

    Ocular Therapeutix™ To Report Third Quarter 2019 Financial Results

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter ended September 30, 2019 financial results on Tuesday, November 12, 2019. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to review the Company’s financial results and provide a general business update. The live webcast can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.

  • Business Wire

    Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has granted non-statutory stock options to purchase up to an aggregate of 54,000 shares of common stock of Ocular Therapeutix to an additional nine, newly-hired Key Account Mangers supporting the commercial launch of DEXTENZA®. Each stock option was granted effective as of October 31, 2019 and has an exercise price of $3.24 per share, the closing price of Ocular’s common stock on October 31, 2019. Each stock option has a ten-year term and is scheduled to vest over four years, with 25% of the original number of shares vesting on the one-year anniversary of the applicable employee’s employment commencement date and the remainder vesting in equal monthly installments over the three years thereafter, subject to the employee’s continued service to Ocular through the applicable vesting dates.

  • Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for

    Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Moving Average Crossover Alert: Ocular Therapeutix
    Zacks

    Moving Average Crossover Alert: Ocular Therapeutix

    Ocular Therapeutix, Inc. (OCUL) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

  • Business Wire

    Ocular Therapeutix Announces Permanent J-Code for DEXTENZA® (dexamethasone ophthalmic insert) Effective October 1, 2019

    Ocular Therapeutix, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use. Under the Healthcare Common Procedure Coding System (HCPCS), the J-code (J1096) will become effective October 1, 2019 and will replace the previously issued C-code for DEXTENZA (C9048), which became effective July 1, 2019. The Company will retain transitional pass-through status granted for DEXTENZA from CMS.

  • American City Business Journals

    These 9 Massachusetts companies rank among the 'happiest' in the country

    Employees at some of Boston's biggest tech companies are among the happiest workers in the country, according to new data

  • Keep Your Eye on These 4 Healthcare Stocks
    Motley Fool

    Keep Your Eye on These 4 Healthcare Stocks

    The growing eye industry is something investors can’t ignore.

  • Thomson Reuters StreetEvents

    Edited Transcript of OCUL earnings conference call or presentation 7-Aug-19 8:30pm GMT

    Q2 2019 Ocular Therapeutix Inc Earnings Call

  • Read This Before Selling Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares
    Simply Wall St.

    Read This Before Selling Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates

    Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -35.71% and -35.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Allergan Announces FDA Acceptance of Glaucoma Candidate NDA
    Zacks

    Allergan Announces FDA Acceptance of Glaucoma Candidate NDA

    The FDA accepts Allergan's (AGN) NDA seeking approval for Bimatoprost SR. A decision is expected in first half of 2020.